DK2600715T3 - Flydende ST-246-formuleringer og fremgangsmåder - Google Patents

Flydende ST-246-formuleringer og fremgangsmåder Download PDF

Info

Publication number
DK2600715T3
DK2600715T3 DK11815188.5T DK11815188T DK2600715T3 DK 2600715 T3 DK2600715 T3 DK 2600715T3 DK 11815188 T DK11815188 T DK 11815188T DK 2600715 T3 DK2600715 T3 DK 2600715T3
Authority
DK
Denmark
Prior art keywords
formulations
methods
liquid
Prior art date
Application number
DK11815188.5T
Other languages
English (en)
Inventor
Gopi Krishna Kasi
Shanthakumar R Tyavanagimatt
Melialani A C L Stone
William C Weimers
Peter N K Samuel
Tove' C Bolken
Dennis E Hruby
Original Assignee
Siga Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Tech Inc filed Critical Siga Tech Inc
Application granted granted Critical
Publication of DK2600715T3 publication Critical patent/DK2600715T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24071Demonstrated in vivo effect
DK11815188.5T 2010-08-05 2011-08-02 Flydende ST-246-formuleringer og fremgangsmåder DK2600715T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37097110P 2010-08-05 2010-08-05
US201161450359P 2011-03-08 2011-03-08
PCT/US2011/046260 WO2012018810A1 (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods

Publications (1)

Publication Number Publication Date
DK2600715T3 true DK2600715T3 (da) 2020-03-16

Family

ID=45559790

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11815188.5T DK2600715T3 (da) 2010-08-05 2011-08-02 Flydende ST-246-formuleringer og fremgangsmåder

Country Status (15)

Country Link
US (5) US9233097B2 (da)
EP (1) EP2600715B1 (da)
JP (1) JP5898196B2 (da)
KR (1) KR101868117B1 (da)
CN (2) CN103281898A (da)
AR (1) AR082566A1 (da)
AU (1) AU2011285871B8 (da)
BR (1) BR112013002646B1 (da)
CA (1) CA2807528C (da)
DK (1) DK2600715T3 (da)
IL (1) IL224430B (da)
MX (2) MX347795B (da)
SG (3) SG10201506031UA (da)
WO (1) WO2012018810A1 (da)
ZA (1) ZA201300930B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN104414983B (zh) * 2013-08-28 2018-09-04 山东新时代药业有限公司 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺
US10406103B2 (en) 2013-11-19 2019-09-10 Siga Technologies Inc. Rehydration of micronized tecovirmimat monohydrate
KR20170012555A (ko) * 2014-06-12 2017-02-02 더 유니버시티 오브 노트르 담 듀락 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
CA2981873A1 (en) 2015-04-10 2016-10-13 Bae Systems Plc Long range sensor apparatus and method of providing a long range sensor apparatus
CN107638571B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞口服药物组合物及其制备方法
CN107625967B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
CN106407676A (zh) * 2016-09-12 2017-02-15 广东省农业科学院动物科学研究所 一种基于蒙特卡罗模拟的抗菌药物药效计算方法
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US20230082992A1 (en) * 2021-09-11 2023-03-16 Viron Therapeutics LLC Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
US11903962B1 (en) 2023-05-07 2024-02-20 Michael Farber Isoxazoline complexes and compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003215027A1 (en) 2002-03-21 2003-10-08 Regents Of The University Of Minnesota Cyclodextrin compositions and methods of treating viral infections
DK1638938T3 (da) * 2003-06-20 2017-07-31 Siga Tech Inc Forbindelser, præparater og fremgangsmåder til behandling og forebyggelse af orthopoxvirusinfektioner og dermed forbundne sygdomme
JP2008525418A (ja) * 2004-12-23 2008-07-17 ファイザー・リミテッド ケモカインccr5受容体に対して活性を有する8−アザ−ビシクロ(3.2.1)オクタン誘導体
JP2008535862A (ja) * 2005-04-08 2008-09-04 キメリクス,インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
PL2581078T3 (pl) * 2005-10-26 2015-07-31 Cydex Pharmaceuticals Inc Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
AU2007321977A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure
CN101702904A (zh) * 2007-04-23 2010-05-05 西佳技术公司 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法
DK2313111T3 (da) 2008-08-01 2013-12-02 Ventirx Pharmaceuticals Inc Toll-lignende receptoragonistformuleringer og anvendelse deraf

Also Published As

Publication number Publication date
AU2011285871A8 (en) 2015-05-14
WO2012018810A9 (en) 2012-04-05
KR20130135836A (ko) 2013-12-11
US20180185514A1 (en) 2018-07-05
JP2013532729A (ja) 2013-08-19
ZA201300930B (en) 2015-11-25
BR112013002646B1 (pt) 2022-01-04
SG10201506031UA (en) 2015-09-29
US20200138974A1 (en) 2020-05-07
EP2600715A4 (en) 2016-04-20
CA2807528C (en) 2018-09-25
WO2012018810A1 (en) 2012-02-09
JP5898196B2 (ja) 2016-04-13
US10864282B2 (en) 2020-12-15
CA2807528A1 (en) 2012-02-09
SG187243A1 (en) 2013-02-28
MX368106B (es) 2019-09-19
US10576165B2 (en) 2020-03-03
MX2013001389A (es) 2013-06-07
CN106074370A (zh) 2016-11-09
IL224430B (en) 2019-09-26
SG10202105262QA (en) 2021-06-29
EP2600715A1 (en) 2013-06-12
MX347795B (es) 2017-05-12
US20140011854A1 (en) 2014-01-09
CN103281898A (zh) 2013-09-04
US10124071B2 (en) 2018-11-13
US20160082128A1 (en) 2016-03-24
AU2011285871B8 (en) 2015-05-14
US9907859B2 (en) 2018-03-06
BR112013002646A2 (da) 2013-02-04
US9233097B2 (en) 2016-01-12
EP2600715B1 (en) 2019-12-11
AU2011285871B2 (en) 2015-04-23
AR082566A1 (es) 2012-12-19
US20190038767A1 (en) 2019-02-07
KR101868117B1 (ko) 2018-06-18
AU2011285871A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
DK2624567T3 (da) Blokinddelingsfremgangsmåde og afkodningsindretning
DK2428450T3 (da) Doseringsmetode og doseringsindretning
BR112012017441A2 (pt) compostos e métodos
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK2648809T3 (da) Naturlige formuleringer
BR112013016969A2 (pt) aparelho e método
DK2544719T3 (da) Cd37-bindingsmolekyler og immunkonjugater deraf
BR112012033478A2 (pt) dispositivo médico
DK3590949T3 (da) Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
DK3664453T3 (da) Billedforudsigelse-afkodningsindretning og billedforudsigelse-afkodningsfremgangsmåde
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK2552434T3 (da) Peptider og anvendelse deraf
BR112013011788A2 (pt) dispositivos e métodos para emanação de líquidos
DK3650125T3 (da) Væskeforstøver og fremgangsmåder
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
BR112012027159A2 (pt) estrutura e método
DK3197164T3 (da) Afkodningsanordning og afkodningsfremgangsmåde
BR112012028015A2 (pt) aparelho e método
DK3167897T3 (da) Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer
DK2544679T3 (da) Pde10-inhibitorer og relaterede sammensætninger og fremgangsmåder
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento